Freshworks Inc. SEC Filings

Freshworks Inc. (FRSH) – Form 4 insider filing, dated July 3, 2025

Chief Accounting Officer Philippa Lawrence disclosed an automatic share withholding transaction executed on July 2, 2025 to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs). The filing records:

• Transaction code F – issuer-withheld shares for taxes, not an open-market sale.
• 2,132 Class A shares withheld at an indicated price of $14.75, implying a value of roughly $32k.
• Post-transaction beneficial ownership stands at 476,115 Class A shares, including 504 shares acquired through the company ESPP for the 11/18/24–5/15/25 period.

The action is routine for equity compensation administration and does not reflect discretionary buying or selling. Ownership after the event represents a sizeable stake, preserving alignment between the executive and shareholders. No derivative transactions were reported. Given the small size relative to Freshworks’ ~297 million outstanding shares, market impact is expected to be negligible.

Freshworks Inc. (FRSH) Form 4 filing discloses that Chief Customer & Marketing Officer Mika Yamamoto sold 4,289 Class A common shares on 1 July 2025 at a weighted-average price of $15.05 under a pre-established Rule 10b5-1 trading plan adopted on 17 Sep 2024.

The transaction represents a relatively small portion of her holdings; following the sale Yamamoto still directly owns 570,487 shares. No derivative transactions were reported. The filing is routine, indicates compliance with Section 16 reporting rules, and does not contain additional operational or financial information about Freshworks.

Chart Industries, Inc. (GTLS) – Form 4 insider filing dated 07/03/2025

Director Spencer S. Stiles reported the receipt of 246 shares of Chart Industries common stock on 07/01/2025. The shares were granted at $0.00 under the company’s 2024 Omnibus Equity Plan and are deferred until a future distribution date. Following the award, Stiles’ direct ownership increased to 2,670 shares. No derivative securities were reported, and there were no open-market purchases or sales disclosed.

The transaction is coded “A” (award/grant) and is considered an exempt acquisition under Rule 16b-3. Because the award is relatively small in absolute terms and was not an open-market purchase, it is unlikely to have a material market impact; however, it does marginally strengthen director-shareholder alignment.

WideOpenWest, Inc. (WOW) – Form 4 insider transaction

Director Phil Seskin reported the acquisition of 3,170 common shares of WideOpenWest on 1 July 2025. The shares were issued at an indicated price of $4.14 per share, representing payment of board retainer and meeting fees in stock rather than cash. Following the transaction, Seskin’s direct beneficial ownership increased to 179,739 shares. No derivative securities were involved and there were no dispositions.

• Transaction code: A (acquisition)
• Ownership type: Direct
• Percent increase in Seskin’s holdings: ≈ 1.8%

The filing is routine and does not disclose any broader strategic developments or financial performance metrics for WOW.

On June 20, 2025, Soligenix, Inc. (Nasdaq: SNGX) filed an 8-K summarizing the results of its 2025 Annual Meeting of Stockholders.

• 2025 Equity Incentive Plan: Approved with 215,332 votes For, 91,937 Against and 57,226 Abstain (1,168,832 broker non-votes). Forms of stock option and restricted stock agreements were filed as Exhibits 10.2 and 10.3.
• Board Elections: All five incumbent directors were re-elected. Support ranged from 329,054 to 332,492 votes For; broker non-votes totaled 1,168,832.
• Say-on-Pay: Executive compensation received advisory approval (303,633 For; 53,830 Against; 7,032 Abstain).
• Auditor Ratification: Cherry Bekaert, LLP was ratified for FY 2025 (1,476,465 For; 54,474 Against; 2,388 Abstain).
• Adjournment Authority: Approved with 1,227,450 For; 295,013 Against; 10,864 Abstain.

No operational updates, financial results or major strategic transactions were disclosed; the filing is primarily governance-oriented and does not materially affect near-term fundamentals.

Universal Electronics Inc. (UEIC) – Insider Form 4, filed 2 Jul 2025

Director Edward K. Zinser reported two equity transactions dated 1 Jul 2025:

• Exercise of 1,250 restricted stock units (Code M) into an equivalent number of common shares, increasing his direct holdings to 47,816 shares.
• Award of 18,437 new restricted stock units (Code A) granted as director compensation; these RSUs vest on 1 Jul 2026 and are now fully reflected in his derivative holdings.

No shares were sold, and there was no cash consideration disclosed. The transactions modestly raise the director’s equity exposure and extend his incentive horizon, but they do not represent a material change to UEIC’s share count or financial position. Investors may view the net share acquisition as a marginally positive governance signal, though the overall impact on valuation is insubstantial.

Freshworks Inc. (FRSH) – Form 4 insider transaction filed 07/02/2025

Director Francis J. Pelzer reported the annual equity retainer granted under the company’s Non-Employee Director Compensation Policy. The award consists of 13,236 Restricted Stock Units (RSUs), each convertible into one share of Class A common stock upon settlement. The grant date is 07/01/2025 and the RSUs vest in full on 07/01/2026, subject to accelerated vesting should the director fail to be re-elected at the next annual meeting.

No shares were sold or otherwise disposed of; the aggregate beneficial ownership for Mr. Pelzer following the award is 43,374 Class A shares, all held directly. The transaction price is recorded as $0, reflecting the compensatory nature of the RSU grant rather than an open-market purchase.

This filing represents routine board compensation and does not alter the company’s capital structure or signal a strategic shift. Investors typically view such grants as neutral from a valuation standpoint, although continued equity awards do incrementally align director interests with shareholder value.

Freshworks Inc. (FRSH) filed a Form 4 disclosing that non-employee director Randy Gottfried received an annual equity grant of 13,236 Class A RSUs on 01-Jul-2025. The award, made under the company’s Non-Employee Director Compensation Policy, carries an exercise/price of $0 and converts 1-for-1 into common shares. The RSUs vest in full on 01-Jul-2026, or earlier should the director fail to be re-elected at the next annual meeting. After the grant Mr. Gottfried’s direct beneficial ownership rises to 53,920 shares. No derivative security transactions were reported. The filing is routine, reflects standard board compensation and results in de-minimis dilution relative to FRSH’s ~300 million shares outstanding.

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).

The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.

Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.

Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA – FURMO-006) is scheduled to begin 2H 2025.

Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.

Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.

Timeline: closing and delivery are expected on or about 3 July 2025.